Vantage logo

Your 2023 wildcard predictions revealed

Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.

Vantage logo

Ash 2022 roundup

Evaluate Vantage's coverage of the Ash 2022 congress.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.